Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Leases (2019 - 2025)

Intellia Therapeutics (NTLA) has disclosed Current Leases for 7 consecutive years, with $26.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 30.79% to $26.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.5 million, a 30.79% increase, with the full-year FY2025 number at $26.5 million, up 30.79% from a year prior.
  • Current Leases was $26.5 million for Q4 2025 at Intellia Therapeutics, down from $27.4 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $38.8 million in Q1 2025 to a low of $7.4 million in Q2 2021.
  • A 5-year average of $17.4 million and a median of $16.9 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: grew 8.86% in 2024, then surged 106.59% in 2025.
  • Intellia Therapeutics' Current Leases stood at $9.1 million in 2021, then soared by 83.11% to $16.7 million in 2022, then grew by 11.47% to $18.6 million in 2023, then rose by 8.86% to $20.2 million in 2024, then skyrocketed by 30.79% to $26.5 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Current Leases are $26.5 million (Q4 2025), $27.4 million (Q3 2025), and $27.0 million (Q2 2025).